Immune responses to human papilloma viruses

Indian Journal of Medical Research

Volumn 130, Issue 3, 2009, Pages 266-276

  Stanley, M A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antibody; Cell mediated immunity; Human papillomavirus; Prophylactic vaccine; VLPs

Indexed keywords

CAPSID PROTEIN L1; INTERFERON; NEUTRALIZING ANTIBODY; SILGARD; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CYTOKINE RELEASE; DISEASE DURATION; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTION CONTROL; INNATE IMMUNITY; NONHUMAN; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; VIRUS REPLICATION; WART VIRUS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CROSS PROTECTION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERONS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 72649101491     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Medzhitov R, Janeway CAJ. Innate immunity: the virtues of a non-clonal system of recognition. Cell 1997; 91: 295-8.
2. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007; 13: 857-61.
3. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005; 32 (Suppl 1): S7-15.
4. Coleman N, Birley HD, Renton AM, Hanna NF, Ryait BK, Byrne M, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994; 102: 768-74.
5. Stanley MA, Scarpini C, Coleman N. Cell mediated immunity and lower genital tract neoplasia. RCOG monograph; 2003.
6. Coleman N, Stanley MA. Characterization and functional analysis of the expression of vascular adhesion molecules in human papillomavirus-related disease of the cervix. Cancer 1994; 74: 884-92.
7. Nicholls PK, Moore PF, Anderson DM, Moore RA, Parry NR, Gough GW, et al. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 2001; 283: 31-9.
8. Jain S, Moore RA, Anderson DM, Gough GW, Stanley MA. Cell-mediated immune responses to COPV early proteins. Virology 2006; 356: 23-34.
9. Nicholls PK, Klaunberg BA, Moore RA, Santos EB, Parry NR, Gough GW, et al. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection. Virology 1999; 265: 365-74.
10. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24 (Suppl 3): S42-51.
11. Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24 (Suppl 1): S16-22.
12. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003; (31): 14-9.
13. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24 Suppl 1: S1-15.
14. Ho GY, Bierman R, Beardsley L, Chang, CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423-8.
15. Liaw KL, Hildesheim A, Burk RD, Gravitt P, Wacholder S, Manos MM, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183: 8-15.
16. Benton, EC, Arends, MJ. Human papillomavirus in the immunosuppressed. In. Lacey C, editor. Papillomavirus reviews: Current research on papillomaviruses. Leeds: Leeds University Press; 1996. p. 271-9.
17. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006; 24 (Suppl 3): S140-6.
18. Fruchter RG, Maiman M, Sedlis A, Bartley L, Arrastia CD. Multiple recurrence of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet Gynecol 1996; 87: 338-44.
19. Fennema JSA, Van Ameijden EJC, Coutinho RA, Van den Hock AJAR. HIV, sexually transmitted diseases and gynaecologic disorders in women: Increased risk for genital herpes and warts among HIV-infected prostitutes in Amsterdam. AIDS 1995; 9: 1071-8.
20. Moscicki AB, Ellenberg JH, Farhat S, xu J. Persistence of human papillomavirus infection in HIV-infected and-uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004; 190: 37-45.
21. Moscicki AB, Ellenberg JH, Crowley-Nowick P, Darragh TM, xu J, Fahrat S. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 2004; 190: 1413-21.
22. Moscicki AB, Ellenberg JH, Farhat S, xu J. Persistence of human papillomavirus infection in HIV-infected and-uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004; 190: 37-45.
23. de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002; 62: 472-9.
24. Welters MJ, de Jong A, van den Eeden SJ, van der Hulst JM, Kwappenberg KM, Hassane S, et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003; 63: 636-41.
25. Welters MJP, van der Logt P, van den Eeden SJF, Kwappenberg KMC, Drijfhout JW, Fleuren GJ, et al. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer 2006; 118: 950-6.
26. Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, et al. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997; 175: 927-31.
27. Evans CA, Bauer S, Grubert T, Brucker C, Baur S, Heeg K, et al. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immuno Immunther 1996; 42: 151-60.
28. Alexander M, Salgaller ML, Celis E, Sette A, Barnes WA, Rosenberg SA, et al. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am J Obstet Gynecol 1996; 175: 1586-93.
29. Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus- specific cytotoxic T-lymphocytes. Cancer Res 1997; 57: 2943-50.
30. Nakagawa M, Stites DP, Palefsky JM, Kneass Z, Moscicki AB. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses. Clin Diagn Lab Immunol 1999; 6: 494-8.
31. Nakagawa M, Stites DP, Patel S, Farhat S, Scott M, Hills NK, et al. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000; 182: 595-8.
32. Stern Y, Felipovich A, Cotton RT, Segal K. Immunocompetency in children with recurrent respiratory papillomatosis: prospective study. Ann Otol Rhinol Laryngol 2007; 116: 169-71.
33. Laffort C, Le Deist F, Favre M, Caillat-Zucman S, Radford-Weiss I, Debre M, et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency. Lancet 2004; 363: 2051-4.
34. Cho YS, Kang JW, Cho M, Cho CW, Lee S, Choe YK, et al. Down modulation of IL-18 expression by human papillomavirus type 16 E6 oncogene via binding to IL-18. FEBS Lett 2001; 501: 139-45.
35. Lee SJ, Cho YS, Cho MC, Shim JH, Lee KA, Ko KK, et al. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells. J Immunol 2001; 167: 497-504.
36. Knowles G, O'Neil BW, Campo MS. Phenotypical characterization of lymphocytes infiltrating regressing papillomas. J Virol 1996; 70: 8451-8.
37. Hong K, Greer CE, Ketter N, Van Nest G, Paliard x. Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts. J Virol 1997; 71: 6427-32.
38. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999; 9: 423-30.
39. Wideroff L, Schiffman MH, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995; 172: 1425-30.
40. Carter JJ, Wipf GC, Hagensee ME, McKnight B, Habel LA, Lee SK, et al. Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts. J Infect Dis 1995; 172: 11-8.
41. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996; 174: 927-36.
42. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 1911-9.
43. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994; 86: 494-9.
44. Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13: 324-7.
45. Moore RA, Nicholls PK, Santos EB, Gough GW, Stanley MA. Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination. J Gen Virol 2002; 83: 2299-301.
46. Amella CA, Lofgren LA, Ronn AM, Nouri M, Shikowitz MJ, Steinberg BM. Latent infection induced with cottontail rabbit papillomavirus. A model for human papillomavirus latency. Am J Pathol 1994; 144: 1167-71.
47. Campo MS, Jarrett WF, O'Neil W, Barron RJ. Latent papillomavirus infection in cattle. Res Vet Sci 1994; 56: 151-7.
48. Maran A, Amella CA, Di Lorenzo TP, Auborn KJ, Taichman LB, Steinberg BM. Human papillomavirus type 11 transcripts are present at low abundance in latently infected respiratory tissues. Virology 1995; 212: 285-94.
49. Abramson AL, Nouri M, Mullooly V, Fisch G, Steinberg BM. Latent human papillomavirus infection is comparable in the larynx and trachea. J Med Virol 2004; 72: 473-7.
50. Paavonen J, Jenkins D, Bosch Fx, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-70.
51. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2002; 2: 59-65.
52. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002; 169: 3242-9.
53. Da Silva DM, Fausch SC, Verbeek JS, Kast WM. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fc{gamma} receptors and contributes to acquisition of T cell immunity. J Immunol 2007; 178: 7587-97.
54. Lenz P, Lowy DR, Schiller JT. Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur J Immunol 2005; 35: 1548-56.
55. Yang R, Murillo FM, Cui H, Blosser R, Uematsu S, Takeda K, et al. Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol 2004; 78: 11152-60.
56. Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, et al. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 1999; 274: 5810-22.
57. Yang R, Murillo FM, Delannoy MJ, Blosser RL, Yutzy WH 4th, Uematsu S, et al. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 2005; 174: 7912-9.
58. Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002; 14: 432-6.
59. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 2007; 7: 79-89.
60. Arany I, Goel A, Tyring SK. Interferon response depends on viral transcription in human papillomavirus-containing lesions. Anticancer Res 1995; 15: 2865-9.
61. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000; 275: 6764-9.
62. Um SJ, Rhyu JW, Kim EJ, Jeon KC, Hwang ES, Park JS. Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett 2002; 179: 205-12.
63. Ronco, LV, Karpova, AY, Vidal, M, Howley, PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998; 12: 2061-72.
64. Li S, Labrecque S, Gauzzi MC, Cuddihy AR, Wong AH, Pellegrini S, et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999; 18: 5727-37.
65. Alazawi W, Pett M, Arch B, Scott L, Freeman T, Stanley MA, et al. Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Res 2002; 62: 6959-65.
66. Chang YE, Laimins LA. Interferon-inducible genes are major targets of human papillomavirus type 31: insights from microarray analysis. Dis Markers 2001; 17: 139-42.
67. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 2001; 75: 4283-96.
68. Kobayashi A, Greenblatt RM, Anastos K, Minkoff H, Massad LS, Young M et al. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004; 64: 6766-74.
69. Adurthi S, Krishna S, Mukherjee G, Bafna UD, Devi U, Jayshree RS. Regulatory T Cells in a spectrum of HPV-induced cervical lesions: Cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma. Am J Reprod Immunol 2008; 60: 55-65.
70. Shope RE. Immunization of rabbits to infectious papillomatosis. J Exp Med 1937; 65: 607-24.
71. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 24: 5571-83.
72. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65.
73. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93: 284-92.
74. Yang R, Murillo FM, Lin KY, Yutzy WH4, Uematsu S, Takeda K, et al. Human papillomavirus type-16 virus-like particles activate complementary defense responses in key dendritic cell subpopulations. J Immunol 2004; 173: 2624-31.
75. Yan M, Peng J, Jabbar IA, Liu x, Filgueira L, Frazer IH, et al. Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-kappaB-mediated signalling, moderated by TGF-beta. Immunol Cell Biol 2005; 83: 83-91.
76. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-8.
77. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
78. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69: 3959-63.
79. Suzich JA, Ghim SJ, Palmer Hill FJ, White WI, Tamura JK, Bell JA, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92: 11553-7.
80. Ghim S, Newsome J, Bell J, Sundberg JP, Schlegel R, Jenson AB. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Exp Mol Pathol 2000; 68: 147-51.
81. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007; 13: 857-61.
82. Stanley MA, Moore RA, Nicholls PK, Santos EB, Thomsen L, Parry N, et al. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine 2001; 19: 2783-92.
83. Fraser C, Tomassini JE, xi L, Golm G, Watson M, Giuliano AR, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 2007; 25: 4324-33.
84. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25: 4931-9.
85. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24: 5937-49.
86. Hammitt LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25: 6958-64.
87. Smith JF, Brownlow M, Brown M, Kowalski R, Esser MT, Ruiz W, et al. Antibodies from women immunized with Gardasil ((R)) cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007; 3: 109-15.